성선자극호르몬방출호르몬 유도체 치료를 받는 진성성조숙증 여아의 1년간 IGF-1, IGFBP-3 혈중농도의 변화
Serum IGF-1 and IGFBP-3 Levels in Central Precocious Puberty Girls Treated with Gonadotropin Releasing Hormone Agonist
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
목 적:진성성조숙증으로 성선자극호르몬방출호르몬 유도체 치료를 받는 여아에서 치료 1년간의 혈중 IGF-1, IGFBP- 3 농도를 알아보고자 하였다. 방 법:2007년부터 2010년까지 원광대학교 산본병원에서 진성성조숙증으로 진단받아 1년간 성선자극호르몬방출호르몬 유도체 치료를 받고 있는 26명의 여아를 대상으로 하였으며 그들의 키, 골연령, 혈중 IGF-1, IGFBP-3 농도를 6개월 마다 측정하여 변화를 관찰 하였다. 결 과:진단시 혈중 IGF-1, IGFBP-3 농도는 302.90±102.54 ng/mL, 3103.58±705.08 ng/mL이었다. 치료 6개월 후의 혈중 IGF-1과 IGFBP-3의 농도는 약간 감소하였고 치료 1년 뒤에는 IGF-1은 증가하고 IGFBP-3는 치료 시작 전 보다 감소하였으나 통계적 유의성은 없었다. 결 론:성선자극호르몬방출호르몬유도체 사용으로 적절히 성호르몬이 억제되면서 정상적인 성장속도를 유지하였으며 혈중 IGF-1, IGFPB-3 농도는 지속적으로 일정하여 유지되었다.
Abstract
Purpose:To investigate the changes of serum IGF-1 and IGFBP-3 levels during one year gonadotropin releasing hormone agonist (GnRHa) treatment in central precocious puberty (CPP) girls. Methods:From 2007 through 2009, twenty six girls were enrolled in this study. They were diagnosed as central precocious puberty and were treated with GnRHa (Leuprolide acetate) for one year. Their height, bone age, serum IGF-1, and IGFBP-3 levels were evaluated every 6 months. Results:At the time of diagnosis, their mean serum levels of IGF-1 and IGFBP-3 were 302.90±102.54 ng/mL and 3,103.58±705.08 ng/mL. At 6month after treatment, the serum IGF-1 and IGFBP-3 levels were slightly decreased. One year later, IGF-1 concentrations were more increased than before treatment and IGFBP-3 levels were decreased (P=NS). But it was not statistically significant. Conclusion:Gonadal suppression with gonadotropin releasing hormone inversely influenced circulating IGF-1 and IGFBP-3 levels. But serum IGF-1 and IGFBP-3 levels were maintained relatively steady levels preserving normal height velocity.(J Korean Soc Pediatr Endocrinol 2011;16:20-23)
참고문헌 (16)
- Belgorosky A, "Irreversible increase of serum IGF-1 and IGFBP-3 levels in GnRH-dependent precocious puberty of different etiologies: implications for the onset of puberty", Horm Res, 49, pp.226~232 (1998)
- Wiedemann E, "Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man", J Clin Endocrinol Metab, 42, pp.942~952 (1976)
- Rosenfield RI, "Relationship of somatomedin-C concentrations to pubertal changes", J Pediatr, 103, pp.723~728 (1983)
- Ho KY, "Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations", J Clin Endocrinol Metab, 64, pp.51~58 (1987)
- Zadik Z, "The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals", J Clin Endocrinol Metab, 30, pp.513~516 (1985)
- Harris DA, "Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist", J Clin Endocrinol Metab, 61, pp.152~159 (1985)
- Pescovitz OH, "Somatomedin-C in accelerated growth of children with precocious puberty", J Pediatr, 107, pp.20~25 (1985)
- Mansfield MJ, "Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty", J Clin Endocrinol Metab, 66, pp.3~9 (1988)
- Juul A, "Serum insulin-like growth factor I (IGF-I) and IGF- binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate)", J Clin Endocrinol Metab, 80, pp.3059~3067 (1995)
- Sklar CA, "Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion", J Clin Endocrinol Metab, 73, pp.734~738 (1991)
- Kanety H, "Insulin-like growth factor-I and IGF binding protein-3 remain high after GnRH analogue therapy in girls with central precocious puberty", Clin Endocrinol (Oxf), 45, pp.7~12 (1996)
- DiMartino-Nardi J, "The effect of long-acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty", J Clin Endocrinol Metab, 73, pp.902~906 (1991)
- Saggese G, "Combination treatment with growth hormone and gonadotropin-releasing hormone analogs in short normal girls", J Pediatr, 126, pp.468~473 (1995)
- Pasquino AM, "Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone", J Clin Endocrinol Metab, 85, pp.619~622 (2000)
- Blum WF, "Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion", J Clin Endocrinol Metab, 76, pp.1610~1616 (1993)
- Juul A, "Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation", J Clin Endocrinol Metab, 80, pp.2534~2542 (1995)